Atlas Trials

Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients

Clinical trial NCT02354313 · UNKNOWN

Trial details

NCT number
NCT02354313
Sponsor
Fondazione Italiana Linfomi - ETS
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
MANTLE CELL LYMPHOMA
Start date
2010-05-01
Primary completion
2017-12-01
Enrollment
300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.